PTCD2

Across TCGA pan-cancer cohorts, PTCD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTCD2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PTCD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTCD2 expression acts as an unfavorable survival marker.

BLCA, STAD, and UCEC are the cancer types where PTCD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.051	0.684	<.001	24	view →
STAD	OS	Median	IV	0.111	0.433	.002	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTCD2–BLCA (OS)

Open the BLCA breakdown →